2 weeks Ago By ABMN Staff
KalVista Pharmaceuticals, Inc. ( NASDAQ:KALV – Get Free Report )’s stock price gapped up before the market opened on Friday . The stock had previously closed at $10.
00, but opened at $10.50. KalVista Pharmaceuticals shares last traded at $12.
17, with a volume of 1,002,742 shares trading hands. Analyst Ratings Changes KALV has been the subject of several recent analyst reports. Cantor Fitzgerald reissued an “overweight” rating on shares of KalVista Pharmaceuticals in a report on Monday, September 9th.
Needham & Company LLC reissued a “buy” rating and set a $32.00 price objective on shares of KalVista Pharmaceuticals in a report on Friday, September 6th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $20.
00 price target on shares of KalVista Pharmaceuticals in a research report on Friday, September 6th. Check Out Our Latest Report on KALV KalVista Pharmaceuticals Trading Up 23.4 % KalVista Pharmaceuticals ( NASDAQ:KALV – Get Free Report ) last issued its quarterly earnings data on Thursday, September 5th.
The specialty pharmaceutical company reported ($0.87) EPS for the quarter, topping analysts’ consensus estimates of ($0.91) by $0.
04. As a group, research analysts forecast that KalVista Pharmaceuticals, Inc. will post -3.
35 earnings per share for the current fiscal year. Insiders Place Their Bets In other news, insider Christopher Yea sold 7,102 shares of the stock in a transaction that occurred on Monday, August 19th. The stock was sold at an average price of $12.
01, for a total transaction of $85,295.02. Following the transaction, the insider now owns 84,467 shares in the company, valued at approximately $1,014,448.
67. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link . In other news, CEO Benjamin L.
Palleiko sold 7,352 shares of KalVista Pharmaceuticals stock in a transaction that occurred on Monday, September 9th. The stock was sold at an average price of $12.19, for a total value of $89,620.
88. Following the sale, the chief executive officer now directly owns 250,800 shares of the company’s stock, valued at $3,057,252. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink .
Also, insider Christopher Yea sold 7,102 shares of KalVista Pharmaceuticals stock in a transaction on Monday, August 19th. The stock was sold at an average price of $12.01, for a total transaction of $85,295.
02. Following the sale, the insider now directly owns 84,467 shares in the company, valued at approximately $1,014,448.67.
The disclosure for this sale can be found here . Over the last 90 days, insiders have sold 30,804 shares of company stock worth $372,112. 12.
30% of the stock is owned by corporate insiders. Institutional Inflows and Outflows Institutional investors have recently bought and sold shares of the business. Frazier Life Sciences Management L.
P. boosted its stake in KalVista Pharmaceuticals by 11.8% during the fourth quarter.
Frazier Life Sciences Management L.P. now owns 3,622,294 shares of the specialty pharmaceutical company’s stock worth $44,373,000 after buying an additional 383,435 shares during the last quarter.
Capital World Investors purchased a new position in KalVista Pharmaceuticals during the first quarter worth about $17,370,000. Entropy Technologies LP acquired a new position in KalVista Pharmaceuticals in the 1st quarter valued at about $121,000. Great Point Partners LLC purchased a new stake in shares of KalVista Pharmaceuticals in the 2nd quarter valued at approximately $15,768,000.
Finally, Price T Rowe Associates Inc. MD increased its holdings in shares of KalVista Pharmaceuticals by 4.5% during the 1st quarter.
Price T Rowe Associates Inc. MD now owns 22,142 shares of the specialty pharmaceutical company’s stock worth $263,000 after buying an additional 944 shares during the last quarter. KalVista Pharmaceuticals Company Profile ( Get Free Report ) KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of small molecule protease inhibitors for diseases with unmet needs in the United States.
The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors. Featured Stories Receive News & Ratings for KalVista Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for KalVista Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter .
.
